İmuran 50 mg and Tofacitinib: interaction and safety
This source-based reference is not a personal treatment recommendation. The relevance and management of an interaction depend on the exact products, route, dose and clinical situation.
Interaction mechanism
Combining potent immunosuppressive treatment can add infection and other immunosuppression risks.
Clinical significance and safety
Tofacitinib labeling does not recommend combination with potent immunosuppressants such as azathioprine or ciclosporin, the ingredient represented by İmuran 50 mg. The concern is added immunosuppression rather than a claim that every conventional anti-inflammatory medicine is prohibited. Specialist review is needed before any treatment change.
Using this information
This is a source-based reference record, not a recommendation to combine, stop or change medicines. A missing interaction record does not establish safe use. A qualified healthcare professional should consider the exact products, doses, other medicines and individual health circumstances.